AllBioPharmaMedTechDebtPublic/M&A

Abcuro

Adicet Bio

AgomAb Therapeutics

Allena Pharmaceuticals

Antios Therapeutics

ArQule

CathWorks

cCAM Biotherapeutics

Check-Cap

CytoReason

Dynacure

Eloxx Pharmaceuticals

Enlivex Therapeutics

Eyevensys

EyeYon

Fore Bio

ForSight VISION6 Inc

Genocea

IMEL Biotherapeutics

Immunic Therapeutics

Kamari Pharma

Keros

Kite Pharma

Levation

LogicBio

Lutris Pharma

Mereo BioPharma

Metabomed

OCON Medical

Opiant

PACT Pharma

Precirix

Prevail Therapeutics

ProQR

Protalix

Raziel Therapeutics

ReWalk

Saniona

Silverback Therapeutics

Soligenix

Stargazer Pharmaceuticals

Step Pharma

Stimatix

Stride Bio

Sweetch

TargEDys

UroGen

V-Wave

Vascular Graft Solutions

VBI Vaccines

Abcuro

Abcuro is a clinical stage biotechnology company developing first-in-class immunotherapies for autoimmune diseases and cancer through precise modulation of effector cytotoxic T and NK cells. These cells can be specifically targeted as they express the receptor KLRG1 (killer cell lectin-like receptor G1).

Area:BioPharma

Status:Private

Adicet Bio

Adicet Bio is a bio-pharmaceutical company focused on the development of next-generation cell immunotherapies for the treatment of cancer. In January 2016, Adicet Bio acquired Applied Immune Technologies (“AIT”) which develops T-cell receptor (TCR) mimicking antibodies.

Area:BioPharma

Status:Public (NASADAQ: ACET)

AgomAb Therapeutics

AgomAb is developing antibody therapies that induce regeneration of damaged tissues, including fibrosis.

Field:BioPharma

Status:Private

Allena Pharmaceuticals

Allena Pharmaceuticals (NASDAQ:ALNA) is dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic disorders that affect the kidney. The company is focused on metabolic disorders that result in excess accumulation of certain metabolites, such as oxalate and urate, that can cause kidney stones, damage the kidney, and potentially lead to chronic kidney disease, or CKD, and end-stage renal disease.

Field:BioPharma

Status:Public (NASADAQ: ALNA)

Antios Therapeutics

Antios Therapeutics is a biopharmaceutical company focused on the development of innovative therapies to treat and cure viral diseases.

Field:BioPahrma

Status:Private

ArQule

ArQule is a bio-pharmaceutical company engaged in the research and development of targeted therapeutics to treat cancers and certain rare diseases.

Field:BioPharma

Status:Acquired by Merck

CathWorks

CathWorks is developing an image-based functional flow reserve (FFR) measurement during coronary catheterization, replacing the pressure-wire based, drug-induced measurement currently performed. CathWorks angiogram-based FFR (FFRangio) has met the need for a less invasive FFR assessment tool, to improve real-time functional assessment leading to treatment decisions, and to make coronary catheterization procedures safer, shorter, more accurate and comprehensive.

Field:Medical Devices

Status:Private

cCAM Biotherapeutics

cCAM Biotherapeutics develops novel immunotherapies for cancer. cCAM’s lead agent, CM-24, is an immunomodulatory antibody that blocks a novel immune checkpoint, thereby harnessing  the patient’s immune system to attack tumors. In July 2015, the company was acquired by Merck.

Field:BioPharma

Status:Acquired by Merck

Check-Cap

Check-Cap is developing a solution for Colorectal Cancer Screening. The Check-Cap pill requires no unpleasant bowel preparation or invasive procedures and is expected to detect clinically significant polyps within the same range of accuracy as a standard colonoscopy.

Field:Medical Devices

Status:Public (NASDAQ:CHEK)

CytoReason

CytoReason is a technology company advancing pharmaceutical R&D through practical application of computational cell-level models of the human body.

Field:Digital Health

Status:Private

Dynacure

Dynacure is a biotechnology company developing antisense drugs for Centronuclear Myopathies (CNM), a debilitating rare disease affecting children and young adults.

Field:BioPharma

Status:Private

Eloxx Pharmaceuticals

Eloxx Pharmaceuticals focuses on the discovery, development and commercialization of compounds for the treatment of genetic diseases caused by nonsense mutations.

Field:BioPharma

Status:PUBLIC (NYSE: ELOX)

Enlivex Therapeutics

Enlivex Therapeutics is developing cell-based therapies for the induction of immune tolerance. Its lead program is in clinical development for graft-versus-host disease.

Field:BioPharma

Status:Public (NASADAQ: ENLV)

Eyevensys

Eyevensys develops non-viral gene therapy treatments for ophthalmology.

Field:BioPharma

Status:Private

EyeYon

EyeYon Medical develops innovative medical devices for the treatment of corneal edema.

Field:Medical Devices

Status:Private

Fore Bio

Fore Bio identifies tumor-specific driver mutations, based on a functional assay that detects dysregulated signaling in cancer cells.

Field:BioPharma

Status:Private

ForSight VISION6 Inc

V6 is developing an accommodating intraocular lens for placement in patients’ eyes post-cataract surgery.

Field:MedTech

Status:Private

Genocea

Genocea is pioneering neoantigen immunotherapies; Genocea’s mission is to help conquer cancer through targeted vaccines and immunotherapies. Their  ATLAS™ platform enables them to make differentiated cancer immunotherapies.

Field:BioPharma

Status:PUBLIC (NYSE:GNCA)

IMEL Biotherapeutics

IMEL Biotherapeutics, is developing a cell-based therapy which represents a new paradigm for the treatment of patients with mitochondrial disorders. Using its proprietary Mitochondrial Replaced Cells technology, IMEL will enable to treat multiple patients with mitochondrial genetic or age-related disorders.

Download IMEL’s company profile

Field:BioPharma

Status:Private

Immunic Therapeutics

Immunic Therapeutics is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases.

Field:BioPharma

Status:Public (NYSE:IMUX)

Kamari Pharma

Kamari Pharma is a biopharmaceutical company aiming to develop and commercialize proprietary small molecule (SMC) inhibitors of TRPV3, a cation channel expressed primary in keratinocytes, for the treatment of dermatological conditions with unmet need.

Click here to read Kamari’s Profile

Field:BioPharma

Status:Private

Keros

Keros is a biopharmaceutical company focused on treatments for rare muscle diseases. Its lead program is a small molecule for the treatment of FOP, an ultra-rare skeletal disease.

Field:BioPharma

Status:Public (NYSE:KROS)

Kite Pharma

Kite Pharma is a publicly traded, clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products with a primary focus on engineered autologous T-cell therapy (CARs and TCRs), designed to restore the immune system’s ability to recognize and eradicate tumors.

Field:BioPharma

Status:Acquired by Gilead

Levation

Levation is developing a topical Oxymetazoline for cosmetic eye lifts.

Field:BioPharma

Status:Private

LogicBio

LogicBio is developing its proprietary gene therapy platform in order to provide lifelong cures for serious, early-onset rare diseases by combining the best of gene therapy and gene editing. Its GeneRide™ technology enables nuclease-free and promoterless site-specific integration of a therapeutic gene into the genome, allowing durable gene expression in dividing cells.

Field:BioPharma

Status:Public (NASDAQ:LOGC)

Lutris Pharma

utris-Pharma is developing LUT014, a topical B-Raf Inhibitor, a proprietary, first-in-class, small molecule allowing administration of EGFR (Epidermal Growth Factor Receptor) Inhibitors to patients without interruptions caused by typical cutaneous side effects.

Field:BioPharma

Status:Private

Mereo BioPharma

Mereo BioPharma is developing and commercializing new therapies for oncology and rare diseases, focusing on bone/musculoskeletal, respiratory and endocrine indications.

Field:BioPharma

Status:Public (NASDAQ: MREO)

Metabomed

Metabomed is a drug discovery company in the field of cancer metabolism with a proprietary target identification platform based on computational biology and metabolomics. Metabomed focuses on targets which are synthetically lethal for biomarker- defined tumors.

Field:BioPharma

Status:Private

OCON Medical

OCON Medical is developing a next-gen intra-uterine device that is currently in clinical testing.

Field:MedTech

Status:Private

Opiant

Opiant is a pharmaceutical company with a mission to create best-in-class medicines for the treatment of addictions and drug overdose.

Field:BioPharma

Status:Public (NASDAQ:OPNT)

PACT Pharma

PACT Pharma is a bio-pharmaceutical company focused on the development of personalized T cell therapies targeting neo-antigens for as cancer treatments.

Field:BioPharma

Status:Private

Precirix

Precirix (Formerly Camel-IDS) is a private, clinical-stage biopharmaceutical company dedicated to extending and improving the lives of cancer patients by designing and developing novel radiopharmaceuticals, using camelid-derived single-domain antibodies (sdAb) labeled with radioisotopes.

Field:BioPharma

Status:Private

Prevail Therapeutics

Prevail is developing gene therapies for patients with Parkinson’s disease and other neurodegenerative diseases

Field:BioPharma

Status: Acquired by Eli Lilly

ProQR

ProQR is an RNA therapeutics platform focused on rare inherited retinal diseases of childhood.

Field:BioPharma

Status:Public (NYSE:PRQR)

Protalix

Protalix is a biopharmaceutical company that specializes in the manufacture of recombinant therapeutic proteins through its ProCellEx plant cell-based protein expression system. Using ProCellEx, Protalix is developing a proprietary pipeline of biobetter and biosimilar recombinant proteins that target large, established markets and that rely upon known biological mechanisms of action.

Field:BioPharma

Status:Public (NYSE: PLX)

Raziel Therapeutics

Raziel Therapeutics is a clinical-stage pharmaceutical company developing a proprietary drug for the treatment of local fat reduction. The company is targeting obesity and related indications.

Field:BioPharma

Status:Private

ReWalk

The ReWalk™ is a robotic exoskeleton that allows paraplegics to bring walking into their daily lives once again. Culminating over a decade of research and development, the ReWalk system represents the first truly practical, real-world, walking solution for people with lower limb disabilities.

Field:MedTech

Status:Public (NASDAQ: RWLK)

Saniona

Saniona is a rare disease biopharmaceutical company focused on research, development, and commercialization of treatments for the central nervous system. 

Field:BioPharma

Status:Public (OMX: SANION)

Silverback Therapeutics

Silverback is developing next-generation antibody-drug conjugates as immuno-oncology treatments for cancer.

Field:BioPharma

Status:Public (NASDAQ: SBTX)

Soligenix

Soligenix is a late-stage biopharmaceutical company committed to developing and commercializing products to treat rare diseases where there is an unmet medical need.

Field:BioPharma

Status:Public (NASDAQ: SNGX)

Stargazer Pharmaceuticals

Stargazer Pharmaceuticals is an ophthalmic biotech company focused on the development of a novel treatment option for Stargardt’s disease, a genetic orphan retinal disease with significant unmet medical needs.

Field:BioPharma

Status:Private

Step Pharma

Step Pharma is a biotechnology company discovering and developing proprietary small molecule therapeutics for the treatment of auto-immune diseases. Step’s lead program is selective modulators against specific immune cell populations which are the main drivers of auto-immune diseases.

Field:BioPharma

Status:Private

Stimatix

Stimatix is developing the Stimatix GI AOS (Artificial Ostomy Sphincter) series, a product line with unique ostomy appliances that improves the quality of life for individuals with stomas.

Field:MedTech

Status:Private

Stride Bio

Stride’s novel gene therapy pipeline targets diseases with significant unmet need and is designed to overcome the current limitations of first-generation gene therapies, with a current focus on rare disorders.

Field:Biopharma

Status:Private

Sweetch

Sweetch is developing a telemedicine platform for outcome prediction and clinical intervention in diabetics.

Field:Mobile Health

Status:Private

TargEDys

TargEDys develops microbiome-based treatments for eating disorders and weight management.

Field:BioPharma

Status:Private

UroGen

UroGen is a clinical-stage specialty pharmaceutical company focused on developing innovative sustained release formulations for uro-oncology.

Field:BioPharma

Status:Public (NASDAQ: URGN)

V-Wave


V-Wave has developed a miniature valve, which is implanted by catheterization into the left ventricle of the heart, to reduce the pressure on the muscle by controlling the blood flow between the heart chambers in patients who are frequently hospitalized with heart attacks.

Field:MedTech

Status:Private

Vascular Graft Solutions

VGS is focused on the development and commercialization of innovative technologies for coronary and peripheral revascularization surgeries.

Field:Medical Devices

Status:Private

VBI Vaccines

VBI Vaccines is a commercial-stage biopharmaceutical company developing next generation vaccines to address unmet needs in infectious diseases and immuno-oncology.

Field:BioPharma

Status:Public (NASDAQ:VBIV)